Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

por Lanke, Shankar, Shoaf, Susan E.
Publicado 2019

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function

por Shoaf, Susan E, Bricmont, Patricia, Mallikaarjun, Suresh
Publicado 2014

Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults

por Shoaf, Susan E., Bricmont, Patricia, Dandurand, Ann
Publicado 2017

Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters

por Shoaf, Susan E., Bricmont, Patricia, Repella Gordon, Jennifer
Publicado 2021

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial

por Shoaf, Susan E., Chapman, Arlene B., Torres, Vicente E., Ouyang, John, Czerwiec, Frank S.
Publicado 2017

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4

por Devuyst, Olivier, Chapman, Arlene B., Shoaf, Susan E., Czerwiec, Frank S., Blais, Jaime D.
Publicado 2017

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects

por Mallikaarjun, Suresh, Wells, Charles, Petersen, Carolyn, Paccaly, Anne, Shoaf, Susan E., Patil, Shiva, Geiter, Lawrence
Publicado 2016

The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations

por Perrone, Ronald D., Chapman, Arlene B., Oberdhan, Dorothee, Czerwiec, Frank S., Sergeyeva, Olga, Ouyang, John, Shoaf, Susan E.
Publicado 2020

A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD

por Perrone, Ronald D., Chapman, Arlene B., Oberdhan, Dorothee, Czerwiec, Frank S., Sergeyeva, Olga, Ouyang, John, Shoaf, Susan E.
Publicado 2020

Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial

por Schaefer, Franz, Mekahli, Djalila, Emma, Francesco, Gilbert, Rodney D., Bockenhauer, Detlef, Cadnapaphornchai, Melissa A., Shi, Lily, Dandurand, Ann, Sikes, Kimberly, Shoaf, Susan E.
Publicado 2019

Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults

por Matuskey, David, Gallezot, Jean-Dominique, Nabulsi, Nabeel, Henry, Shannan, Torres, Kristen, Dias, Mark, Angarita, Gustavo A, Huang, Yiyun, Shoaf, Susan E, Carson, Richard E, Mehrotra, Shailly
Publicado 2022

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

por Woodhead, Jeffrey L., Brock, William J., Roth, Sharin E., Shoaf, Susan E., Brouwer, Kim L.R., Church, Rachel, Grammatopoulos, Tom N., Stiles, Linsey, Siler, Scott Q., Howell, Brett A., Mosedale, Merrie, Watkins, Paul B., Shoda, Lisl K.M.
Publicado 2017